Contract Revenue from Collaboration (Details) (Pfizer, USD $) In Millions, unless otherwise specified	3 Months Ended
Mar. 31, 2013
Pfizer
Revenue from Collaboration Agreement
License revenue	$ 2.0
Cumulative milestone payments received	5.0
Potential milestone payments which the company could receive under the agreement	$ 9.5
Royalty percentage of net sales	8.00%
Maximum patent term extension	5 years

The cumulative amount of cash proceeds received from milestone payments pursuant to a collaboration agreement.

No definition available.

Name:	onxx_CumulativeMilestonePayments
Namespace Prefix:	onxx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Represents the maximum period up to which the expiration of patent may be extended under the statues that provide for patent term extensions.

+ References

No definition available.

+ Details

Name:	onxx_MaximumPatentExpiryExtensionPeriod
Namespace Prefix:	onxx_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Potential future payments which can be earned upon achievement of milestones in a collaboration agreement.

+ References

No definition available.

+ Details

Name:	onxx_PotentialAdditionalPaymentsUnderLicensingAndCollaborationAgreement
Namespace Prefix:	onxx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Represents the percentage of royalty net sales of the product which the third party has agreed to pay the reporting entity.

+ References

No definition available.

+ Details

Name:	onxx_RoyaltyPercentageOfNetSales
Namespace Prefix:	onxx_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Revenue earned during the period relating to consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1(e))

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

+ Details

Name:	us-gaap_LicensesRevenue
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration